Merck Tops Third-Quarter Expectations as Keytruda and Gardasil Outperform
Merck exceeded third-quarter expectations, with Keytruda and Gardasil performing better than expected.
Related stories
Stora Enso Q3 sales fall 2% on divestments
M impact | EARNINGS | Oct 30, 2026, 06:41 AM UTC
TAIEX Hits Over 2-Month Low, Suffers Monthly Loss
The TAIEX, Taiwan’s benchmark stock index, slumped 1,157 points, or 2.5%, to close at 45,212 on Friday, extending losses from the previous session and tracking a sharp fall in US s
H impact | EARNINGS | Oct 30, 2026, 06:40 AM UTC
Offshore Yuan Strongest Since 2022
The offshore yuan traded around 6.65 per dollar, reaching its strongest level since April 2022, supported by robust export growth and exporters converting dollar holdings into yuan
L impact | EARNINGS | Oct 30, 2026, 06:37 AM UTC
Sanofi Adjusted EPS Rises 22% in Q3 2026
Sanofi reported adjusted earnings per share for the third quarter of 2026, up 22%.
M impact | EARNINGS | Oct 30, 2026, 06:35 AM UTC
Sanofi Q3 business EPS €3.55
Sanofi reported Q3 business EPS of €3.55; consensus was €2.81.
M impact | EARNINGS | Oct 30, 2026, 06:30 AM UTC
Sanofi reports Q3 net sales
Sanofi reported Q3 net sales of €14,44 MDS; Vara consensus was €13,25 MDS.
M impact | EARNINGS | Oct 30, 2026, 06:30 AM UTC